Plain-English translation of NCT06736717 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called given together with a chemotherapy combination called for people with advanced pancreatic cancer who have never received treatment before. The medication works by targeting a specific protein in cancer cells. Researchers hope this combination will help people with pancreatic cancer live longer and control their disease better.
Pancreatic cancer is a very serious disease, and current treatments help people live an average of 11 months. Almost all pancreatic cancers have a mutation in a gene called KRAS that makes tumors grow and resist treatment. There are currently no approved drugs that specifically target this KRAS mutation, so doctors are urgently looking for new treatment approaches to improve survival.
You likely qualify if…
You likely don't qualify if…
You would take as a pill by mouth for 5 days, then have a 9-day break, creating a 14-day cycle. On day 1 of each cycle, you would also receive chemotherapy intravenously at the study center. You would need to provide a tissue sample (from an existing biopsy or a fresh biopsy during screening) so researchers can study your cancer. You would have regular visits for blood tests, physical exams, and imaging scans to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States